Enhancement of GABAergic function is the primary mechanism of important therapeutic agents such as benzodiazepines, barbiturates, neurosteroids, general anaesthetics and some anticonvulsants. Despite their chemical diversity, many studies have postulated that these agents may bind at a common or overlapping binding site, or share an activation domain. Similarly, we found that flavan-3-ol esters act as positive modulators of GABA A receptors, and noted that this action resembled the in vitro profile of general anaesthetics. In this study we further investigated the interactions between these agents.
Introduction
GABA type A (GABAA) receptors are ligand-gated chloride channels consisting of a heteropentameric assembly of proteins derived from a family of 19 genes, namely a1 -6, b1-3, g1-3, d, p, e, q and r1-3 (Simon et al., 2004) . Common topography of these subunits is a large extracellular amino-terminal domain, four transmembrane segments (TM1-TM4) and a long intracellular domain between TM3 and TM4. The chloride channel is delimited by the second transmembrane domain of each of the five subunits, with the large extracellular domain constituting the agonist/antagonist orthosteric binding sites (McKernan and Whiting, 1996; Miller and Smart, 2010) . In addition, the receptor contains a variety of allosteric sites that can modulate its function by altering the energy barrier required for conformational changes in the chloride channel (Johnston, 2005) . Many important therapeutic agents such as benzodiazepines, barbiturates, loreclezole, and general anaesthetics like etomidate and propofol bind to these allosteric sites to produce an enhancement of GABAA receptor function.
Functional GABAA channels require the presence of a and b subunits, but the vast majority of naturally expressed receptors also contain a g subunit (McKernan and Whiting, 1996) . Interestingly, agents such as barbiturates, neurosteroids, loreclezole and etomidate can positively modulate ab type receptors, suggesting that their corresponding binding sites lie within one of these subunits, or their interface (Malherbe et al., 1990; Thompson et al., 1996; Rudolph and Antkowiak, 2004; Belelli and Lambert, 2005) . Furthermore, while the presence of a g subunit is necessary for high-affinity modulation by benzodiazepine ligands, later studies proved that these drugs can also exert low-affinity (mM) modulation of ab GABAA receptors (Stevenson et al., 1995; Walters et al., 2000) . Although much evidence suggests the presence of discrete binding sites for these agents, many reports also suggested a common mechanism or overlapping sites. For example, mutational studies have identified a glycine at position 219 on the second transmembrane domain of the b2 subunit as fundamental for anaesthetic modulation of GABA currents (Chang et al., 2003) . These authors found a linear correlation between the volume of the amino acid at this position and the loss of modulation by etomidate, propofol, pentobarbital and alphaxalone. Similarly, modulation by etomidate, propofol and loreclezole can be greatly reduced when the N265 residue at b-TM2 is replaced by serine, indicating a common mechanism. This position, however, seems to have little influence on the modulation by barbiturates and neurosteriods Belelli et al., 1997; 1999; Siegwart et al., 2003; Desai et al., 2009 ). Also, several mutational studies at M286 on b-TM3 demonstrated its relevance for both propofol and etomidate modulatory activity, although modulation by loreclezole, neurosteroids and barbiturates remained unaffected (Krasowski et al., 1998; Siegwart et al., 2003) .
Similarly, the contribution of the a subunit to anaesthetic action has been examined by site-directed mutagenesis. For example, Drafts and Fisher (2006) found that the mutation T69K in a6 subunit reduced both pentobarbital and etomidate agonist action, and mutations in a-TM1 alter sensitivity to neurosteroids (Hosie et al., 2006; Akk et al., 2008) . Li and colleagues (2006) utilized a radiolabelled photoreactive etomidate analogue to identify residues involved in the binding of etomidate. Their results pointed not only at the previously mentioned M286 in b2-TM3, but also at M236 in a1-TM1 (and the homologous methionines in a2,3,5), an amino acid not previously implicated in the binding of this anaesthetic. Later functional studies revealed that substitution of this residue by a bulky amino acid such as tryptophan significantly reduces the modulation elicited by etomidate, but not by alphaxalone or pentobarbital (Stewart et al., 2008) .
Studies involving site-directed mutagenesis intrinsically carry the paradox of whether the mutated residue being studied is directly involved in ligand-protein interactions, or is involved in the allosteric changes taking place as a consequence of the binding process, making the results difficult to interpret. Whereas the use of techniques such as photoaffinity labelling, radioligand binding competition or the simple use of specific antagonists may provide a deeper insight into unravelling the mysteries of these potentially overlapping binding sites. We have previously described a series of flavan-3-ol derivatives as positive modulators of GABA A receptors (Fernandez et al., 2008; Mewett et al., 2009) . The derivative 2S,3R-trans 3-acetoxy-4′-methoxyflavan (Fa131) demonstrated positive allosteric properties over a range of GABAA subunit combinations, and in particular had a higher efficacy at a2-containing GABAA receptors. We noted at the time that the mode of action of Fa131 resembled that of other GABAA modulators such as neurosteroids, barbiturates and anaesthetics such as etomidate. In this present study, we carried out mutational studies on 'anaesthetic-influencing' residues to test their role in flavan-elicited modulation of GABAA receptors. Furthermore, we discovered a new flavan derivative, namely 2S,3S-cis 3-acetoxy-3′,4′-dimethoxyflavan (Fa173), featuring antagonist properties. Fa173 is the first reported ligand to inhibit the modulation of GABA by etomidate, loreclezole, diazepam and flavans, but not thiopentone or 5a-pregnan-3a-ol-20-one (THP), indicating that these drugs may share a common binding pocket or activation domain.
Methods

DNA constructs and ligands
cDNA for human a1, b2 and g2L GABAA receptor subunits subcloned into pCDM8 were provided by Dr Paul Whiting (Merck, Sharpe and Dohme Research Labs, Harlow, UK). The protocol for in vitro transcription of cRNA has been described previously (Hall et al., 2005) . Briefly, cDNA vectors were linearized with the appropriate restriction endonucleases and capped transcripts were produced from linearized plasmids using the mMessage mMachine T7 transcription kit (Ambion, Austin, TX, USA). cRNA was diluted and stored in diethylpyrocarbonate-treated water at -80°C until use. Sitespecific mutations were introduced into the cDNAs of the GABAA receptor subunits using QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Mutagenic oligonucleotides used were (5′ to 3′): b2N265S, ACAATCAG CACCCACCTCAGGGAAAC; a1M236A, CCTGCCGTGCATA GCGACAGTTATTCTC; a1M236W, CCTGCCGTGCATATGG ACAGTTATTCTC. Mutant clones were submitted to complete sequencing to corroborate the successful incorporation of the point mutation and absence of spurious mutations.
Fa131 and Fa173 >99% purity ( Figure 1 ) were synthesized in our laboratories as previously described (Mewett et al., 2009) . Diazepam was purchased from Apin Chemicals Ltd. (Oxon, UK), sodium thiopental was from Jurox (Rutherford, NSW, Australia), loreclezole and etomidate [(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester] were from Tocris (Ellisville, MO, USA). Propofol was purchased from Sigma-Aldrich (St Louis, MO, USA). THP ((3a,5b)-3-hydroxy-pregnan-20-one) was kindly provided by Dr Peter Burden, Department of Pharmacology, University of Sydney.
Two-electrode voltage-clamp recordings from Xenopus oocytes
Recombinant receptors were expressed in Xenopus laevis oocytes; the nomenclature used to identify these receptor types conform to the British Journal of Pharmacology's Guide to Receptors and Channels (Alexander et al., 2011) . The procedure for the harvesting and enzymatic separation of Xenopus laevis oocytes was identical to that described previously (Hall et al., 2005; Fernandez et al., 2008) and was approved by the Animal Ethics Committee of the University of Sydney. Briefly, female X. laevis were anaesthetized by immersion in 0.17% 3-aminobenzoic acid ethyl ester with 0.02% NaCl for 10-15 min, and a lobe of the ovaries was surgically removed. The lobe was rinsed with oocyte releasing buffer 2 (OR2; 82.5 mM NaCl, 2 mM KCl, 1 mM MgCl 2.6H2O, 5 mM HEPES, pH 7.5) and treated with collagenase A (2 mg·mL -1 in OR2, Boehringer Manheim, Germany) for 2 h to separate oocytes from connective tissue and follicular cells. Released oocytes were rinsed in ND96 wash solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl 2.6H2O, 1.8 mM CaCl2, 5 mM HEPES, pH 7.5). Stage V-VI oocytes were injected (Nanoject, Drummond Scientific Co., Broomall, PA, USA) with a total of 3-5 ng of cRNA. When expressing receptors containing a g subunit, a 1:1:2 ratio of a : b : g subunits was used. After the injection, oocytes were incubated at 16°C in ND96 storage solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl 2, 1.8 mM CaCl2, 5 mM HEPES, pH 7.5, supplemented with 2.5 mM pyruvate, 0.5 mM theophylline and 50 mg·mL -1 gentamycin) for 2 days before use in electrophysiological studies.
Currents were recorded using the two-electrode voltage clamp technique as previously described (Walters et al., 2000; Hall et al., 2005) . Oocytes were individually placed in a 100 mL chamber connected to a reservoir bottle containing ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl 2, 1.8 mM CaCl2, 5 mM HEPES, pH 7.5). Glass microelectrodes were made using a micropipette puller (Narishige Scientific Instrument Laboratory, Tokyo, Japan) and filled with 3 M KCl (0.5-2 MW). The oocytes were impaled and the membrane potential was clamped at -60 mV while continuously superfused with ND96 solution (10 mL·min -1 ). Stock solutions of the drugs were prepared in dimethyl sulphoxide (DMSO), except for GABA and sodium thiopental where distilled water was used, and applied into the perfusate until a peak response was reached. DMSO concentration in the perfusate was 0.6% and did not produce any alteration in the recording. Voltage clamp experiments were conducted using a Geneclamp 500 amplifier (Axon Instruments Inc., Foster City, CA, USA). Current amplitudes were calculated off-line using Chart software v3.6 (ADInstruments, NSW, Australia).
Responses to GABA applications were normalized as I% = (I/I max), where I is the peak amplitude of current response and Imax is the maximal current produced by GABA measured in each individual cell. Modulation of GABA-elicited currents was tested by co-applying increasing concentrations of the drugs with a concentration of GABA that produced 3% of maximal activation (EC 3, determined for each cell). Current responses were recorded and normalized as: fractional potentiation = (Idrug -IGABA) / IGABA, where Idrug is the current in the presence of a given concentration of drug, and IGABA is the amplitude of the control GABA current. Finally, experiments involving the antagonist Fa173 were conducted by co-applying GABA EC 3, the positive modulator at a concentration that produced 50% its maximal effect (EC50, determined for each cell), and increasing concentrations of Fa173. Data were normalized according to the equation: % inhibition: 100 ¥ (I mod -Ianta) / (Imod -IGABA), where Ianta is the response in the presence of Fa173, IGABA is the response to GABA alone and Imod is the response to GABA plus positive modulator. In all cases, a 3-5 min washout period was allowed between drug applications to avoid receptor desensitization. Normalized responses were pooled and graphed as mean Ϯ SEM from at least two different batches of injected oocytes. Responses were fitted to the four-parameter logistic equation:
), where I is the peak amplitude of the current elicited by a given concentration of agonist [A] , Imax is the maximum amplitude of the current, EC50 is the concentration required for half-maximal response, and nH is the Hill coefficient (Prism v5 GraphPad Software, San Diego, CA,
Figure 1
Molecular structure of the compounds utilized in the study. 
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USA). Best-fit parameters were first compared by extra-sumof-squares F-test to detect whether an estimated parameter differs among data sets. Individual differences between bestfit values were detected by non-overlapping confidence intervals. All data analyses were conducted using Prism v5 and a P value lower than 0.05 was considered of statistical significance.
Results
Mutational analysis of b2-N265 and a1-M236
The co-injection of mRNA encoding point-mutated subunits of the GABA receptor type A resulted in functional GABAactivated channels. The potency of GABA to activate a1b2N265Sg2L receptors was slightly lower compared with wild-type, but this change was not statistically significant (Table 1) . Conversely, receptors containing a tryptophan point mutation on methionine 236 (a1M236Wb2g2L) were more sensitive to GABA activation as revealed by a significantly lower EC50 (Table 1) . Interestingly, when the same residue was substituted by an alanine, which is much smaller in size, no significant changes in GABA activation were observed (Table 1) . To test for spontaneous channel opening, we applied picrotoxin alone at 1 mM concentration to all receptor types. Interestingly, only a1M236Wb2g2L receptors showed an upward change in baseline, representing about 3-6% of maximal GABA-induced activation (data not shown).
The flavan-3-ol derivative Fa131 potentiated GABAelicited currents at both a1b2g2L and a1b2 wild-type GABAA receptors expressed in Xenopus oocytes. Similarly, the anaesthetic etomidate and the anticonvulsant loreclezole elicited a positive modulatory action on these receptor types in a way resembling the effect of Fa131. Corresponding EC50 values for the modulation of GABA currents at both receptor subtypes were in the low micromolar range for all three drugs, and corresponding concentration-response curves presented high Hill coefficient values. Loreclezole a1b2g2L 9.5 Ϯ 0.9 9.8 Ϯ 2.1 2.2 Ϯ 1.1 5 a1b2 7.4 Ϯ 0.8 11.3 Ϯ 1.1 1.8 Ϯ 0.6 4 a1b2N265Sg2L 3.0 Ϯ 0.5** 24.0 Ϯ 3.8* 1.6 Ϯ 0.6 5 a1M236Wb2g2L 6.1 Ϯ 0.6* 9.3 Ϯ 1.9 1.4 Ϯ 0.4 4 a1M236Ab2g2L 8.7 Ϯ 0.7 12.0 Ϯ 3.5 2.1 Ϯ 0.7 4 *P < 0.05; **P < 0.01; ***P < 0.001; significantly different compared to value at corresponding wild-type receptor. a Note that the normalization method differs between GABA-alone dose-response curves and potentiation by positive modulators.
Point mutation of the 265 serine residue on b2-TM2 proved to form functional channels that exhibited a substantial resistance to the modulatory action of Fa131. Representative current traces depicting this effect are shown in Figure 2A , where the potentiating action of Fa131 (10 mM) is shown at different receptor subunit combinations. Fa131 can potentiate the GABA EC 3 10 times at this concentration at a1b2g2L wild-type GABAA receptors; however, this enhancement was reduced to three times at a1b2N265Sg2L. Full concentration-response curves are shown in Figure 2A right panel. The Fa131 EC 50 was shifted from 9.7 to 18.1 mM, while the maximal potentiation was reduced to half, compared with wild-type, both effects reaching statistical significance (Table 1) . Similarly, the methionine-to-tryptophan substitution at position 236 in a1-TM1 had drastic, but unequal effects on the potentiation induced by this drug. A concentration of 10 mM Fa131 only potentiated GABA currents five times in this case (Figure 2A) , and while the EC 50 was slightly
Figure 2
Potentiation of GABA current responses by Fa131 (A) and etomidate (B) and loreclezole (C) at a1b2g2L, a1b2N265Sg2L, a1M236Wb2g2L and a1M236Ab2g2L GABAA receptors expressed in Xenopus oocytes. Left panels show currents traces (nA vs. min) illustrating the enhancing effects of these drugs at different receptor types. Horizontal bars represent drug application. GABA alone corresponds to EC3, determined for each oocyte expressing each subunit combination, and was approximately 5 mM (a1b2g2L), 7 mM (a1b2N265Sg2L), 0.2 mM (a1M236Wb2g2L) and 3 mM (a1M236Ab2g2L). Current traces shown correspond to 10 mM Fa131, 3 mM etomidate and 10 mM loreclezole application. Right panels are full concentration-response curves for the potentiating effects of these drugs on GABA-elicited currents, at each receptor subtype. Data points represent mean Ϯ SEM (n Ն 4) of peak current response normalized as described in Methods. Data were fitted using four-parameter logistic equation and the best-estimated values for each parameter are detailed in Table 1. shifted to the left (4.6 mM), the maximal enhancement was significantly lowered from 14.7 to 7 times the GABA EC3 ( Figure 2A and Table 1 ). Finally, replacing this same residue by an alanine induced no significant changes in the modulatory action of Fa131 over GABA-elicited currents (Table 1) .
In oocytes expressing wild-type a1b2g2L GABAA receptors, etomidate induced a significant potentiating effect, enhancing GABA EC3 more than 20 times at 3 mM ( Figure 2B ). Both N265S in b2-TM2 and M236W in a1-TM1 mutations substantially impaired the etomidate modulatory action, with 3 mM etomidate having virtually no effect on a1b2N265Sg2L receptors, and only enhancing GABA currents two times at a1M236Wb2g2L ( Figure 2B ). Concentration-response curves for etomidate at both mutated receptors were significantly shifted to the right ( Figure 2B right panel) . Changes in potency were characterized by a significant increase in etomidate EC50 from 3.2 mM at wild-type receptors to 22.0 and 14.2 mM at a1b2N265Sg2L and a1M236Wb2g2L receptors, respectively (Table 1) . Similarly, maximal potentiation induced by this drug was significantly lowered from 28.9 times the GABA EC3 response at wild-type receptors, to approximately 18 times at each of the mutated receptors (Table 1) . However, mutation M236A at a1-TM1 presented no significant changes on etomidate-induced potentiation ( Figure 2B , Table 1 ).
The anticonvulsant loreclezole also potentiates the GABA response at wild-type a1b2g2L GABAA receptors expressed in Xenopus oocytes; 10 mM loreclezole induced a clear enhancement of GABA currents (six times the GABA EC3) as depicted in current traces shown in Figure 2C . The point-mutation N265S at b2 completely abolished the potentiation by 10 mM loreclezole ( Figure 2C ), and produced a significant shift-tothe-right in its concentration-response curve ( Figure 2C right  panel) . Consequently, the EC50 for this drug increased from 9.8 mM at wild-type receptors to 24.0 mM at a1b2N265Sg2L receptors, while the maximal effect achieved decreased from 9.5-to 3-fold potentiation (Table 1 ). In contrast, the mutation M236W at a1-TM1 had less pronounced effects on loreclezole potentiation; 10 mM loreclezole potentiated the corresponding GABA EC3 by three times at a1M236Wb2g2L receptors, compared with the sixfold potentiation in wildtype receptors ( Figure 2C ). The concentration-response curves for loreclezole presented a similar EC50 value at both receptor subtypes, while the maximal potentiation significantly decreased from 9.5 times to 6.1 times at a1M236Wb2g2L receptors (Table 1) . As seen with Fa131 and etomidate, mutation of the methionine 236 at a1-TM1 to an alanine did not affect the modulatory action of loreclezole ( Figure 2C , Table 1 ).
Fa173 is a neutral modulator and antagonizes the modulatory action of flavans
The flavan analogue Fa173 (100 mM) was inactive when applied in the absence of GABA and showed no significant modulatory effects on GABA-elicited (EC3-5 and ECmax) currents at a1b2 or a1b2g2L receptors expressed in Xenopus oocytes. Current traces shown in Figure 3A illustrate the lack of significant effects of Fa173 (1-300 mM) over corresponding GABA EC3 concentrations at these two receptor subunit combinations. Only at very high concentrations, 100 and 300 mM, some weak potentiation of GABA EC3 was evident. This effect reached approximately 20% enhancement over the corresponding GABA-elicited current response ( Figure 3B ). In turn, Fa173 was able to dose-dependently reduce the potentiation of GABA currents induced by Fa131 at both a1b2g2L and a1b2 GABAA receptors ( Figure 4A ,B respectively). For these experiments, we selected a low concentration of GABA (EC3), and combined it with a concentration of Fa131 that produces half its maximal potentiation response (EC50). We then co-applied these two drugs with increasing concentrations of Fa173 and recorded the final current peak amplitude. Representative current traces of these experiments are depicted in Figure 4A ,B. Concentration-response curves for Fa173 inhibitory action over Fa131 potentiation at both receptor subtypes are shown in Figure 4C . Fa173 was equipotent at both receptor subunit combinations (IC50 = 11.4 Ϯ 0.9 mM at a1b2g2L and 7.8 Ϯ 1.2 mM at a1b2), and similarly, its neutralizing efficacy was comparable (maximal inhibition = 100 Ϯ 5% and 93 Ϯ 5%, respectively, Figure 4C ).
Figure 3
Co-application of GABA and the flavan derivative Fa173 at both a1b2 and a1b2g2L GABAA receptors expressed in Xenopus oocytes. (A) Current traces illustrating the effect that Fa173 exerts over GABAelicited currents. Only at very high concentrations Fa173 weakly potentiated GABA responses at both receptor subtypes. GABA applications were 1 mM and 5 mM, at a1b2 and at a1b2g2L, respectively, equivalent to their corresponding EC3. Horizontal bars represent drug application. (B) Histograms depict the percentage of current potentiation over the current response elicited by GABA alone. Columns represent mean Ϯ SEM peak current response (n = 6).
Fa173 antagonizes the potentiation induced by etomidate and loreclezole, but not by propofol, THP or thiopental
Considering the ability of Fa173 to antagonize the potentiating effects of Fa131, we tested its antagonistic profile over a series of well-known GABAA positive modulators. Thus, etomidate, propofol, loreclezole, the neurosteroid THP and the barbiturate thiopental were selected to conduct antagonism experiments. Assays were carried out by co-applying GABA (EC 3) plus modulator (EC50) and Fa173 (increasing concentrations), in order to estimate an inhibitory potency for the antagonist.
Fa173 similarly neutralized the potentiating effects of etomidate at a1b2 and a1b2g2L GABA A receptors ( Figure 5A,B) . Representative current traces shown in Figure 5A ,B depict the potentiation induced by etomidate of the GABA EC3 response, and its subsequent blockade by increasing concentrations of Fa173. The potency of Fa173 to antagonize etomidate was comparable at both receptor subunit combinations (IC 50 = 12.0 Ϯ 1.1 mM and 6.1 Ϯ 1.3 mM, at a1b2g2L and a1b2 receptors, respectively), as was its maximal inhibitory effect (maximal inhibition = 86 Ϯ 8% and 81 Ϯ 5%, respectively) ( Figure 5C ).
Loreclezole can also induce large potentiation of GABAelicited currents at both at a1b2 and a1b2g2L GABA A receptors ( Figure 6 ). This enhancement was antagonized by co-applying increasing concentrations of the antagonist Fa173, as depicted in the current traces shown in Figure 6A ,B. At a1b2g2L receptors, the IC 50 was 6.6 Ϯ 0.2 mM with a maximal inhibition of 99 Ϯ 11%, while at a1b2 the IC50 was 3.8 Ϯ 0.9 mM with a maximal inhibition of 94 Ϯ 4% ( Figure 6C ).
The antagonizing properties of Fa173 were tested against the positive modulatory action of THP, thiopental and propofol at a1b2 and a1b2g2L GABA A receptors (n = 4) (Figure 7 ). Fa173 (1-100 mM) failed to alter the enhancement of the GABA response induced by THP ( Figure 7A ) or by thiopental ( Figure 7B ), at both receptor subtypes. Finally, Fa173 (60 mM) also failed to alter the enhancement of the GABA response induced by propofol (10 mM) at a1b2 and a1b2g2L receptors (n = 3) ( Figure 7C ).
Fa173 blocks the GABA-potentiating effects induced by large, but not low, concentrations of diazepam
It has been well documented that diazepam can enhance GABA-induced currents in a biphasic mode when acting on a1b2g2L GABAA receptors (Walters et al., 2000) , an observation that has been reproduced in our laboratories (Hall et al., 2005) . We selected two concentrations of diazepam to study the high-affinity (100 nM) and low-affinity (100 mM) effects of this drug at a1b2g2L receptors ( Figure 8A,B) . At a concentration of 100 nM, diazepam induced a twofold potentiation of the GABA response, and this enhancement was completely blocked by the co-application of flumazenil 10 mM (93% inhibition), but not by Fa173 100 mM (2% inhibition, n = 3) ( Figure 8A ). However, when diazepam was applied at a high concentration (100 mM), flumazenil produced a mild neutralizing effect (about 10%), while the flavan Fa173 (100 mM) almost completely abolished the potentiation (87% inhibition, n = 3) ( Figure 8B ).
Figure 4
The flavan Fa173 acts as an antagonist of the GABAA positive modulator Fa131 at both a1b2g2L and a1b2 recombinant receptors expressed in Xenopus oocytes. Current traces (nA vs. min) illustrating the concentration-dependent blockade that Fa173 exerts over the potentiating action of Fa131 at (A) a1b2g2L and (B) a1b2 receptors. Drug concentrations were 5 mM GABA and 15 mM Fa131 at a1b2g2L and 1 mM GABA and 10 mM Fa131 at a1b2, equivalent to their corresponding EC3 and EC50, respectively. Horizontal bars represent drug application. (C) Concentration-response curve for Fa173 antagonistic action over Fa131-induced potentiation of GABA currents at both receptor subtypes. Data points represent mean Ϯ SEM peak current response normalized as described in Methods. Data were fitted using four-parameter logistic equation and the bestestimated values for each parameter are: IC50 = 11.4 Ϯ 0.9 mM, maximal inhibition = 100 Ϯ 5%, n = 7 at a1b2g2L; IC50 = 7.8 Ϯ 1.2 mM, maximal inhibition = 93 Ϯ 5%, n = 6 at a1b2. Hill coefficient values were not different from unity and are not reported.
Figure 5
The flavan Fa173 acts as an antagonist of the etomidate-induced enhancement of GABA currents. (A) Current traces (nA vs. min) illustrating the blockade that increasing concentrations of Fa173 exert over the potentiating action of etomidate at a1b2g2L receptors. (B) Current traces (nA vs. min) illustrating the blockade that increasing concentrations of Fa173 exert over the potentiating action of etomidate at a1b2 receptors. Drug concentrations were 3 mM GABA and 10 mM etomidate at a1b2g2L and 1 mM GABA and 10 mM etomidate at a1b2, equivalent to their corresponding EC3 and EC50, respectively. Horizontal bars represent drug application. (C) Concentration-response curves for Fa173 blockade of etomidateinduced potentiation (IC50 = 12.0 Ϯ 1.1 mM and 6.1 Ϯ 1.3 mM, maximal inhibition = 86 Ϯ 8% and 81 Ϯ 5%, at a1b2g2L and a1b2 receptors, n = 6 and 5, respectively).
Figure 6
The flavan Fa173 acts as an antagonist of the loreclezole-induced enhancement of GABA currents. (A) Current traces (nA vs. min) illustrating the blockade that increasing concentrations of Fa173 exert over the potentiating action of loreclezole at a1b2g2L receptors. (B) Current traces (nA vs. min) illustrating the blockade that increasing concentrations of Fa173 exert over the potentiating action of loreclezole at a1b2 receptors. Drug concentrations were 3 mM GABA and 10 mM loreclezole at a1b2g2L and 1 mM GABA and 10 mM loreclezole at a1b2, equivalent to their corresponding EC3 and EC50, respectively. Horizontal bars represent drug application. (C) Concentration-response curves for Fa173 blockade of loreclezoleinduced potentiation (IC50 = 6.6 Ϯ 0.2 mM and 3.8 Ϯ 0.9 mM, maximal inhibition = 99 Ϯ 11% and 94 Ϯ 4%, n = 7 and 5, at a1b2g2L and a1b2 receptors, respectively).
Conversely, at GABAA receptors composed of a1b2 subunits, diazepam potentiates GABA-induced currents in a monophasic manner, consistent with a single 'low-affinity' site. Diazepam (50 mM) induced a fivefold increase in GABAelicited currents at this subunit combination, and this effect was unaffected by flumazenil (10 mM). However, when this dose of diazepam was co-applied with increasing concentrations of Fa173, the potentiation was completely abolished. Fa173 antagonized diazepam with an IC 50 of 2.7 Ϯ 0.8 mM and maximal inhibition of 94 Ϯ 5% (n = 4) ( Figure 8C ).
Discussion
GABA A receptors expressing b2-N265 subunit
Etomidate and loreclezole present enhanced modulatory action at GABAA receptors that contain a b2/3 subunit, and their activity is comparatively weaker at b1 Hill-Venning et al., 1997) . Later studies found that this selectivity was conferred by a single asparagine residue located at position 265 on the second transmembrane domain of the b2 subunit (and equivalent position at b3). When this asparagine is mutated to a serine (homologous amino acid in the b1 subunit), the ability of etomidate and loreclezole to potentiate GABA currents is diminished Wingrove et al., 1994; Belelli et al., 1997) , and, accordingly, knock-in mice carrying either b3N265M or b2N265S present impaired sensitivity to the in vivo actions of these drugs (Jurd et al., 2003; Reynolds et al., 2003; Rudolph and Antkowiak, 2004; Groves et al., 2006) . Notably, mutations at this point do not interfere with the potentiation induced by the neurosteroid alphaxalone and the barbiturate pentobarbitone (Belelli et al., 1999; Siegwart et al., 2003) . In this study, the b2N265S mutant was
Figure 7
The flavan Fa173 failed to antagonize the potentiating effects induced by the neurosteroid THP and the barbiturate thiopental at recombinant a1b2 and a1b2g2L GABAA expressed in Xenopus oocytes. (A) THP (1 mM) induced a potentiation of GABA-elicited currents, which could not be blocked by co-applying the flavan Fa73 at 1, 10 and 100 mM (n = 4). (B) The potentiation induced by thiopental (15 mM) was not affected by the co-application of the agent Fa173 (1-100 mM), at both receptor subtypes (n = 4). (C) Similarly, propofol (10 mM) induced a potentiation of GABA-elicited currents, that could not be blocked by co-applying the flavan Fa73 at 1, 10 and 100 mM (n = 3).
co-expressed with a1 and g2L subunits. As expected, etomidate and loreclezole were less capable of enhancing currents at this mutant receptor, but more interestingly, the modulatory action of Fa131 was also affected by this mutation, suggesting that these agents share a common binding site domain or signal transduction mechanism. Some studies utilizing computational modelling have suggested that this residue could contribute to the binding pocket for etomidate (Campagna-Slater and Weaver, 2007) . However, more recent studies have suggested that N265 is not involved in the binding of etomidate (Li et al., 2006) . As there is no high resolution crystal structure available for the GABAA receptor
Figure 8
The flavan 173 selectively antagonizes the current enhancement induced by diazepam acting on its low-affinity site. (A) Representative current traces showing that Fa173 does not antagonize the potentiating effects of a low concentration of diazepam acting on a1b2g2L receptors, while this effect is completely blocked by flumazenil (left panel). The quantification of the inhibitory effect of both drugs is shown on the right panel (n = 3). (B) Conversely, the response elicited by diazepam at a high concentration is blocked up to 87% by the flavan Fa173, while the co-application of flumazenil only inhibited about 10% of this response (n = 3). (C) At a1b2 receptors, diazepam induces a potentiation of GABA-elicited currents that can be almost completely blocked by the co-application of Fa173, but not flumazenil (left panel) (n = 4). The panel on the right shows the concentration-response curve for this effect (IC50 = 2.7 Ϯ 0.8 mM, maximal inhibition = 94 Ϯ 5%).
complex, the exact role of N265 remains unclear, dampening further speculations on our hypothesis.
GABA A receptors expressing a1-M236 subunit
In 2006, Li and collaborators, utilizing a radiolabelled photoreactive etomidate analogue, identified M236 at a-TM1 and M286 at b-TM3, to be directly involved in the binding of this anaesthetic (Li et al., 2006) . In later work, Stewart et al. (2008) conducted a tryptophan mutation on M236 and characterized the properties of a1M236Wb2g2L receptors, showing that these channels present increased sensitivity to GABA transduction, and reduced etomidate modulation. Our a1M236Wb2g2L GABA A mutant receptors presented very similar characteristics to those described by Stewart et al., including augmented GABA gating, mild spontaneous activity and reduced potentiation by etomidate. Importantly, we found that this mutant was also less sensitive to allosteric modulation by loreclezole, and the flavan-3-ol Fa131, further reinforcing the idea that these three modulators share their binding pocket or activation domain. Interestingly, the mutation M236A did not affect the modulatory properties of etomidate, loreclezole or Fa131. Methionine, the original amino acid, tryptophan and alanine, the chosen mutations, all share the characteristics of non-polar hydrophobic amino acids; however, they differ largely in their molecular size. Thus, it is tempting to speculate that tryptophan impairs drug activity by sterically impeding the accommodation of large aromatic rings, or alternatively by offering nearby residues an intramolecular aromatic interaction, thus weakening the binding of a drug with similar needs. In this line, Stewart et al. (2008) proposed that a a1-M236W mutation mimicked the effects of etomidate on wild-type GABA A receptors. Conversely, alanine has a much smaller side chain that would allow the binding process to remain unaltered.
Fa173 is an antagonist of positive modulators such as Fa131, etomidate and loreclezole
Despite the worldwide use of GABAA receptor positive modulators in human therapy, the development of site-specific antagonists, best defined as neutral modulators, has been scarce. This may be due to the large number of sites for allosteric regulation present in these channels (Johnston, 2005) . For example, positive or negative modulation by benzodiazepine ligands at the high-affinity site can be blocked by the antagonist flumazenil. Similarly, bemegride and 3a,5a-17-phenylandrost-16-en-3-ol have been proposed to be antagonists of the barbiturate and neurosteroid sites, respectively, but these drugs seem to present intrinsic limitations (Schechter, 1984; Mennerick et al., 2004) . In our study, the flavan derivative Fa173 showed characteristics of a specific flavan-site modulator with extremely low efficacy to potentiate GABA-induced currents. Importantly, the main structural requirement for this change in intrinsic activity seems to be a cis conformation at C2 and C3. At recombinant a1b2 and a1b2g2L receptors, Fa173 antagonized the potentiation induced by the positive modulator Fa131. Importantly, Fa173 also antagonized the enhancing effects of etomidate and loreclezole at a1b2 and a1b2g2L receptors, suggesting that these drugs bind to a single binding site. However, it failed to neutralize the potentiating action of the neurosteroid THP, the barbiturate thiopental and the anaesthetic propofol.
As Fa173 had little direct effect on GABA-elicited currents, it is unlikely that this compound acts via binding to the GABA site. Rather, the antagonistic properties of Fa173 are highly selective, and may occur through competition for the etomidate/flavan site; however, further experimentation is needed to clarify the specific mechanism. Despite these reservations, this is, to our knowledge, the first report of a specific neutral modulator for the etomidate/loreclezole site and Fa173 represents a lead compound in the development of novel antagonists.
Diazepam binds to the 'etomidate' site with mM affinity
Both benzodiazepines and b-carbolines have been shown to possess two distinct components when interacting with GABAA receptors. The first component, via the classical benzodiazepine site, possesses high-affinity (nM), is flumazenilsensitive and requires the presence of a1,2,3,5 and g subunits. The second site presents low ligand affinity (mM), is insensitive to blockade by flumazenil and is not dependent on the presence of a g subunit (Malherbe et al., 1990) . It has been hypothesized that this second binding component could respond to an interaction with the etomidate/loreclezole site, as it could be eliminated by mutations at N265 in b2-TM2 (Stevenson et al., 1995; Walters et al., 2000) . Our results corroborate this hypothesis; the flavan Fa173 blocked the effects of etomidate, loreclezole and high concentrations of diazepam at a1b2 and a1b2g2L receptors. Importantly, we demonstrated that the two binding sites to which diazepam interacts with can be selectively blocked by the addition of flumazenil (high-affinity site) and Fa173 (low-affinity site).
Implications for anaesthetic action
Several mutational studies at M286 on b-TM3 led to the proposal that propofol may bind in the M3 domain near b2M286 (Krasowski et al., 1998; Siegwart et al., 2003) . However, the finding that propofol only partially inhibits the affinity labelling of both a1M236 and b2M286 by [ 3 H]-azietomidate suggests that the effect of propofol on the reaction of [ 3 H]-azietomidate with these residues is allosteric rather than direct (Li et al., 2010) . Importantly, the finding that Fa173 blocks potentiation by etomidate but not propofol supports the notion that propofol does not have a direct interaction with the etomidate binding site a1b2g2L in GABA A receptors. Recently, the crystal structure of the bacterial LGIC with propofol bound was published, showing the location to be an inter-subunit cavity between the TM3 and TM4 domains (Nury et al., 2011) . However, it is not yet known whether propofol binds in a similar location at GABA A receptors.
We previously observed that while the intrinsic activity of the flavan Fa131 on GABAA receptors resembled general anaesthetics, its in vivo profile was quite distinct. Unlike drugs such as etomidate, loreclezole and diazepam, Fa131 failed to induce strong sedative and hypnotic effects in mice. Rather, it exerted a robust anxiolytic action, as measured by the elevated plus maze and the light/dark paradigm. This discrepancy can be explained by the higher efficacy of Fa131 to activate GABAA receptors containing an a2 subunit (Fernandez et al., 2008) , as this GABAA receptor subtype is believed to mediate the anxiolytic activity of benzodiazepines and barbiturates (Möhler et al., 2002; Dixon et al., 2008) . In contrast, etomidate and loreclezole present limited a-subunit selectivity and their ability to induce sedation, anaesthesia and seizure protection is markedly subjugated by the activation of all b2/3-containing GABAA receptors, which represent more than 90% of all receptors expressed in the mammalian brain (Rudolph and Antkowiak, 2004; Groves et al., 2006) . Benzodiazepines, such as diazepam, are much used as therapy for anxiety, but this group of substances has also proved useful as anticonvulsants, hypnotics and muscle relaxants. However, this spectrum of pharmacological activities does not all occur in the same dose range, and extensive studies have suggested that the incremental CNS effects of benzodiazepines may be the consequence of gradual nM receptor occupancy (Gardner, 1988; Ito et al., 1993; . The identification of a second mM potentiation component, present in any aXb2/3 subunit combination, thus less specific, indicates the possibility that the deep CNS-depressant actions of benzodiazepines could be the result of their effect, at mM concentrations, on GABAA receptor channels (Walters et al., 2000) . Whether flumazenil does (Hoffman and Warren, 1993) , or does not (Little and Bichard, 1984) , antagonize the anaesthetic effects of benzodiazepines, might reveal whether a double nM/mM potentiation is an essential requirement. However, despite these speculations, the physiological and pharmacological relevance of the low-affinity benzodiazepine site is currently unknown, and, consequently, the development of a sitespecific antagonist such as Fa173 may assist in addressing this question.
Conclusions
In summary, our studies have demonstrated that Fa173 is a selective antagonist that can be used for allosteric modulation of GABAA receptors. Using a combination of mutational studies and this novel ligand, we showed that flavan-3-ol derivatives are potential ligands for etomidate/loreclezolerelated binding sites at GABAA receptors. Furthermore, the low-affinity potentiation induced by benzodiazepines, perhaps related to their high-dose anaesthetic-like effects, can also be explained by a second binding component to this same site.
